Биомаркеры системного воспаления и динамика липидного профиля при различной степени ожирения

Biomarkers of the system inflammation and blood lipids spectrum changes at the patients with obesity of various degree
Цитировать:
Биомаркеры системного воспаления и динамика липидного профиля при различной степени ожирения // Universum: медицина и фармакология : электрон. научн. журн. Хайбуллина З.Р. [и др.]. 2015. № 12 (23). URL: https://7universum.com/ru/med/archive/item/2847 (дата обращения: 21.11.2024).
Прочитать статью:
Keywords: dislipidemia, inflammation factors, obesity, overweight

АННОТАЦИЯ

В статье обсуждаются изменения липидного спектра плазмы крови и биомаркеры системного воспаления (С-реактивный белок (СРБ), интерлейкин-6 (ИЛ-6), фактор некроза опухоли альфа, фибриноген) при различной степени ожирения, а также у лиц с избыточной массой тела. Обследовано 76 женщин в возрасте 49,6±2,8 лет, некурящих, имеющих избыточную массу тела (индекс массы тела – ИМТ=28,2± 0,4 кг/м2) и ожирение I–III степени. Установлено, что снижение липопротеинов высокой плотности и увеличение триглицеридов отмечается у лиц с избыточной массой тела, а ожирение II и III степеней характеризуется практически одинаковой выраженностью дислипидемии. Обнаружены повышенные концентрации СРБ, ИЛ-6, увеличение моноцитов крови, что указывает на развитие системного воспаления при наличии избыточного веса и ожирении. Корреляционный анализ (n=76) показал, что имеется отрицательная корреляционная связь средней силы между уровнем липопротеинов высокой плотности (ЛПВП) и окружностью талии (ОТ): (r= - 0,42), тогда как между ЛПВП и ИМТ эта связь была слабой (r= - 0,18). Связи между уровнем триглицеридов (ТГ) и ИМТ; ТГ и ОТ характеризовались как слабые положительные: r=0,14 и r=0,26 соответственно. Обнаружена достоверная положительная корреляционная связь средней силы между ОТ и СРБ (r=+0,57) и отрицательная, средней силы связь между ОТ и ЛПВП (r= - 0,43) при ожирении II степени. Это свидетельствует о зависимости параметров липидного обмена и уровня СРБ от окружности талии при ожирении.

ABSTRACT

Biomarkers of a system inflammation (C-reactive protein - CRP, interliykin-6 – IL-6, tumor necrosis factor alpha, fibrinogen, whole blood count) and blood lipids spectrum changes at patients with various degree of obesity and also at persons with overweight are discussed in the article. It have surveyed 76 women in the middle age of 49,6±2,8 years old, all of patients were not smoking, with overweight (body mass index – BMI=28,2± 0,4 kg / m2) and I–III class of obesity.

It is established, that decreasing of triglycerides, increasing of high density lipoproteins appears already at overweight; II and III classes of obesity are characterized by identical expressiveness of dyslipidemia. High concentration of CRP, IL-6 and monocytes are found out in persons with overweight and obesity that specifies development of a system inflammation. The correlation analysis (n=76) has shown, that there was a negative correlation connection of average force between a high density lipoproteins (HDL) level and waist circumference (WC): (r = - 0,42) whereas correlation connection between HDL and BMI was negative and weak
(r = - 0,18). Connections between a level of triglycerides (TG) and BMI; TG and WC were characterized as weak positive: r=0,14 and r=0,26 accordingly. There were positive with overage force correlation connection between WC and CRP (r=+0,57); negative, average force correlation connection between WC and HDL (r= - 0,43) at II class obesity. This data suggests that parameters of lipidomic profile and CRP depends on WC at obesity.

 


Список литературы:

1. Литвинова Л.С., Василенко М.А., Затолокин П.А. и др. Продукция адипоцитокинов у больных морбидным ожирением при различных способах лечения // Сахарный диабет. – 2014. – № 3. – С. 51–59. doi:10.14341/DM2014351-59.
2. Рекомендации экспертов всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома, второй пересмотр. – М., 2009. – 32 с.
3. Хайбуллина З.Р., Абдуллаева С.Д., Собиров Ж.Г. Сравнительная оценка уровня факторов воспаления при периферическом и коронарном атеросклерозе // Вестник НГПУ. – 2015. – № 4. – С. 68–76. DOI:http://dx.doi.org/10.15293/2226-3365.1504.07
4. Bastard J.P., Maachi M., Lagathu C. et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance // Eur. Cytokine Netw. – 2006. – № 17(1). – Р. 4–12.
5. Bouloumié A., Curat C.A., Sengenès C. et al. Role of macrophage tissue infiltration in metabolic diseases // Curr. Opin. Clin. Nutr. Metab. Care. – 2005. – № l; 8 (4). – Р. 347–354.
6. Bouwman J.J., Visseren F.L., Bouter K.P. et al. Infection-induced inflammatory response of adipocytes in vitro // Int. J. Obes. (Lond). – 2008. –№ 32 (6). – Р. 892–901. doi: 10.1038/ijo.2008.36.
7. Calabrò P., Golia E., Yeh E.T. CRP and the risk of atherosclerotic events // Semin Immunopathol. – 2009. – № 31(1). – Р. 79–94. doi: 10.1007/s00281-009-0149-4.
8. Calabro P., Yeh E.T. Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk // Curr. Hypertens. Rep. – 2008. – №10(1). – Р. 32–38.
9. Calabro P., Yeh E.T. Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ // Subcell Biochem. – 2007. – № 42. –Р. 63–91.
10. Chen F., Wang W., Teng Y . et al. Relationship between high-sensitivity
C-reactive protein and obesity/metabolic syndrome in children // Zhonghua Liu Xing Bing Xue Za Zhi. – 2014. – № 35(6). – Р. 621–625.
11. Esser N., Legrand-Poels S., Piette J. et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes // Diabetes Res. Clin. Pract. – 2014. – № 105(2). – Р. 141–150. doi: 10.1016/j.diabres.2014.04.006.
12. Furuhashi M., Saitoh S., Shimamoto K. et al. Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases // Clin. Med. Insights. Cardiol. – 2015. – № 2;8(Suppl 3). – Р. 23–33. doi: 10.4137/CMC.S17067.
13. Haberka M., Gąsior Z. Carotid extra-media thickness in obesity and metabolic syndrome: A novel index of perivascular adipose tissue: Extra-media thickness in obesity and metabolic syndrome // Atherosclerosis. – 2015. – № 239(1). –Р. 169–177. doi: 10.1016/j.atherosclerosis.
14. Hadaegh F., Khalili D., Ghasemi A. et al. Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men // Nutr. Metab. Cardiovasc Dis. – 2009. – № 19(6). – Р. 401–408. doi: 10.1016/j.numecd.2008.09.003.
15. Heilbronn L.K., Campbell L.V. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity // Curr. Pharm. Des. – 2008. – № 14(12). –Р. 1225–1230.
16. Lakka H.M., Laaksonen D.E., Lakka T.A. et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men // JAMA. – 2002. – № 288. – Р. 2709–2716.
17. Lemieux I., Poirier P., Bergeron J. et al. Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology? // Can. J. Cardiol. – 2007. – № 23 Suppl B. – Р. 23B–31B.
18. Li Z., Deng M.L., Tseng C.H. et al. Hypertriglyceridemia is a practical biomarker of metabolic syndrome in individuals with abdominal obesity // Metab. Syndr. Relat. Disord. – 2013. – № 11(2). – Р. 87-91. doi: 10.1089/met.2012.0090.
19. Martínez-Martínez E., Jurado-López R., Cervantes-Escalera P. et al. Leptin, a mediator of cardiac damage associated with obesity // Horm. Mol. Biol. Clin. Investig. – 2014. – № 18(1). – Р. 3–14. doi: 10.1515/hmbci-2013-0060.
20. Matsuda M., Shimomura I. Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases // Rev. Endocr. Metab. Disord. – 2014. – № 15 (1). –Р. 1–10. doi: 10.1007/s11154-013-9271-7.
21. Munk P.S., Larsen A.I. Inflammation and C-reactive protein in cardiovascular disease // Tidsskr. Nor. Laegeforen.– 2009. – № 11;129 (12). – Р. 1221–1224. doi: 10.4045/tidsskr.08.0011.
22. Oliver E., McGillicuddy F., Phillips C. et al. The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA // Proc. Nutr. Soc. – 2010. –№ 69 (2). –Р. 232–243. doi: 10.1017/S0029665110000042.
23. Onat A., Hergenç G., Sansoy V. et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders // Atherosclerosis. – 2003. – № 168 (1). – Р. 81–89.
24. Rizzo M., Corrado E., Coppola G. et al. The predictive role of C-reactive protein in patients with hypertension and subclinical atherosclerosis // Intern. Med. J. – 2009. – № 39 (8). – Р. 539–545. doi: 10.1111/j.1445-5994.2009.01955.x.
25. Salazar M.R., Carbajal H.A., Espeche W.G. et al. Identification of cardiometabolic risk: visceral adiposity index versus triglyceride/HDL cholesterol ratio // Am. J. Med. – 2014. – № 127 (2). – Р. 152–157. doi: 10.1016/j.amjmed.2013.10.012.
26. Shimano H. Obesity and atherosclerosis // Nippon Rinsho. – 2009. – № l.67. – P. 333–337.
27. Tsiotra P.C., Boutati E., Dimitriadis G. et al. High insulin and leptin increase resistin and inflammatory cytokine production from human mononuclear cells // Biomed. Res. Int. – 2013. – № 20. – Р. 487081. doi: 10.1155/2013/487081.
28. Vargas-Robles H., Rios A., Arellano-Mendoza M. et al. Antioxidative Diet Supplementation Reverses High-Fat Diet-Induced Increases of Cardiovascular Risk Factors in Mice // Oxid. Med. Cell. Longev. – 2015. – № 2015. – Р. 467–471.
29. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome // Endocr. Rev. – 2000. – № 21. – Р. 697–738.

 


References:

1. Litvinova L.S., Vasilenko M.A., Zatolokin P.A. et al. Adipocytokines production at patients with morbid obesity at various ways of treatment. Sakharnyi diabet [Diabetes]. 2014, no. 3, pp. 51–59. doi:10.14341/DM2014351-59. (in Russian).
2. Recommendations of experts of the all-Russia scientific organization of cardiologists for diagnostics and treatment of a metabolic syndrome, the second revision. Moscow. 2009. 32 p.
3. Khaybullina Z.R., Abdullaeva S.D., Sobirov J.G. Comparative evaluation of inflammation factors at the peripheral and coronary atherosclerosis. Vestnik NGPU [Novosibirsk State Pedagogical University Bulletin]. 2015, no. 4. pp. 68–76. DOI: http://dx.doi.org/10.15293/2226-3365.1504.07 (in Russian).
4. Bastard J.P., Maachi M., Lagathu C. et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw., 2006, no. 17(1), pp. 4–12.
5. Bouloumié A., Curat C.A., Sengenès C. et al. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care, 2005, no. l; 8(4), pp. 347–354.
6. Bouwman J.J., Visseren F.L., Bouter K.P. et al. Infection-induced inflammatory response of adipocytes in vitro. Int J Obes (Lond), 2008, no.32(6), pp. 892–901. doi: 10.1038/ijo.2008.36.
7. Calabrò P., Golia E., Yeh E.T. CRP and the risk of atherosclerotic events. Semin Immunopathol. 2009, no. 31(1), pp. 79–94. doi: 10.1007/s00281-009-0149-4.
8. Calabro P., Yeh E.T. Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep., 2008, no. 10(1), pp. 32–38.
9. Calabro P., Yeh E.T. Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. Subcell Biochem. 2007, no. 42, pp. 63–91.
10. Chen F., Wang W., Teng Y . et al. Relationship between high-sensitivity
C-reactive protein and obesity/metabolic syndrome in children. Zhonghua Liu Xing Bing Xue Za Zhi. 2014, no. 35(6), pp. 621–625.
11. Esser N., Legrand-Poels S., Piette J. et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014, no. 105(2), pp. 141–150. doi: 10.1016/j.diabres.2014.04.006.
12. Furuhashi M., Saitoh S., Shimamoto K. et al. Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases. Clin Med Insights Cardiol. 2015, no. 2;8 (Suppl 3), pp. 23–33. doi: 10.4137/CMC.S17067.
13. Haberka M., Gąsior Z. Carotid extra-media thickness in obesity and metabolic syndrome: A novel index of perivascular adipose tissue: Extra-media thickness in obesity and metabolic syndrome. Atherosclerosis. 2015, no. 239(1), pp. 169–177. doi: 10.1016/j.atherosclerosis.
14. Hadaegh F., Khalili D., Ghasemi A. et al. Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men. Nutr Metab Cardiovasc Dis. 2009, no. 19(6), pp. 401–408. doi: 10.1016/j.numecd.2008.09.003.
15. Heilbronn L.K., Campbell L.V. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des., 2008, no. 14(12), pp. 1225–1230.
16. Lakka H.M., Laaksonen D.E., Lakka T.A. et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002, no. 288, pp. 2709–2716.
17. Lemieux I., Poirier P., Bergeron J. et al. Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology? Can J Cardiol. 2007, no. 23 Suppl B, pp. 23B–31B.
18. Li Z., Deng M.L., Tseng C.H. et al. Hypertriglyceridemia is a practical biomarker of metabolic syndrome in individuals with abdominal obesity. Metab Syndr Relat Disord. 2013, no. 11(2), pp. 87–91. doi: 10.1089/met.2012.0090.
19. Martínez-Martínez E., Jurado-López R., Cervantes-Escalera P. et al. Leptin, a mediator of cardiac damage associated with obesity. Horm Mol Biol Clin Investig., 2014, no. 18(1), pp. 3–14. doi: 10.1515/hmbci-2013-0060.
20. Matsuda M., Shimomura I. Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases. Rev Endocr Metab Disord. 2014, no. 15(1), pp. 1–10. doi: 10.1007/s11154-013-9271-7.
21. Munk P.S., Larsen A.I. Inflammation and C-reactive protein in cardiovascular disease. Tidsskr Nor Laegeforen. 2009, no. 11;129(12), pp. 1221–1224. doi: 10.4045/tidsskr.08.0011.
22. Oliver E., McGillicuddy F., Phillips C. et al. The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA. Proc Nutr Soc. 2010, no.69(2), pp. 232–243. doi: 10.1017/S0029665110000042.
23. Onat A., Hergenç G., Sansoy V. et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis. 2003, no. 168(1), pp. 81–89.
24. Rizzo M., Corrado E., Coppola G. et al. The predictive role of C-reactive protein in patients with hypertension and subclinical atherosclerosis. Intern Med J., 2009, no. 39(8), pp. 539–545. doi: 10.1111/j.1445-5994.2009.01955.x.
25. Salazar M.R., Carbajal H.A., Espeche W.G. et al. Identification of cardiometabolic risk: visceral adiposity index versus triglyceride/HDL cholesterol ratio. Am J Med. 2014, no. 127(2), pp. 152–157. doi: 10.1016/j.amjmed.2013.10.012.
26. Shimano H. Obesity and atherosclerosis. Nippon Rinsho. 2009, no. l.67, pp. 333–337.
27. Tsiotra P.C., Boutati E., Dimitriadis G. et al. High insulin and leptin increase resistin and inflammatory cytokine production from human mononuclear cells . Biomed Res Int. 2013, no. 20, P. 487081. doi: 10.1155/2013/487081.
28. Vargas-Robles H., Rios A., Arellano-Mendoza M. et al. Antioxidative Diet Supplementation Reverses High-Fat Diet-Induced Increases of Cardiovascular Risk Factors in Mice. Oxid Med Cell Longev. 2015, no. 2015, pp. 467–471.
29. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000, no. 21, pp. 697–738.

 


Информация об авторах

д-р мед. наук, зав. отделом биохимии с группой микробиологии АО «Республиканский специализированный центр хирургии им. В. Вахидова», 700115, Республика Узбекистан, г. Ташкент, ул. Фархадская, 10

Doctor of medicine, chief of biochemistry and microbiology department, AS “V. Vakhidov Republican specialized center of surgery”, 700115, Uzbekistan, Tashkent, Farhadskaja st., 10

канд. биол. наук., с. н. с., отдел биохимии с группой микробиологии АО «Республиканский специализированный центр хирургии им. В. Вахидова», 700115, Республика Узбекистан, г. Ташкент, ул. Фархадская, 10

Candidate of Biological Sciences, senior research scientist, biochemistry and microbiology department, AS “V. Vakhidov Republican specialized center of surgery”, 700115, Uzbekistan, Tashkent, Farhadskaja str., 10

канд. биол. наук, доцент, кафедра биологической, биоорганической и неорганической химии Ташкентского педиатрического медицинского института, 100140, Республика Узбекистан, г. Ташкент, Юнусабадский район, ул. Богишамол, 223

Candidate of Biological Sciences, associate professor, biochemistry, bioorganic and inorganic chemistry department of Tashkent pediatric medical institute, 100140, Uzbekistan, Tashkent, Yunusabad region, Bagishamal str., 223

канд. хим. наук, ассистент, кафедра биологической, биоорганической и неорганической химии Ташкентского педиатрического медицинского института, 100140, Республика Узбекистан, г. Ташкент, Юнусабадский район, ул. Богишамол, 223

Candidate of Chemical Sciences, assistant, biochemistry, bioorganic and inorganic chemistry department of Tashkent pediatric medical institute, 100140, Uzbekistan, Tashkent, Yunusabad region, Bagishamal str., 223

Журнал зарегистрирован Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор), регистрационный номер ЭЛ №ФС77–64808 от 02.02.2016
Учредитель журнала - ООО «МЦНО»
Главный редактор - Конорев Марат Русланович.
Top